Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Aetna    AET

AETNA (AET)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Goldman M&A head Sykes joins management committee

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 11:07pm CET

(Reuters) - Gene Sykes, global head of Goldman Sachs Group Inc's (>> Goldman Sachs Group, Inc.) mergers and acquisitions business, has been named to the investment bank's management committee, according to an internal memo.

(Reuters) - Gene Sykes, global head of Goldman Sachs Group Inc's (>> Goldman Sachs Group, Inc.) mergers and acquisitions business, has been named to the investment bank's management committee, according to an internal memo.

The 54-year-old investment banker joins 28 other executives on the powerful committee, which includes Chief Executive Lloyd Blankfein and Chief Operating Officer Gary Cohn, and influences decisions about Goldman's business strategy and operations.

Sykes' appointment comes just nine days after the departure of another prominent Goldman banker, Yoel Zaoui, was announced in a separate internal memo. Zaoui shared the title of M&A co-head with Sykes and had also been on the management committee.

Sykes, who is based in Los Angeles, is also chairman of the global technology, media and telecommunications department of the investment banking division. He is a member of Goldman's internal Business Standards Committee.

The Goldman veteran joined the firm in 1984 and became a partner in 1992. He has advised on several high-profile deals, including Walt Disney Co's (>> The Walt Disney Company) acquisition of Pixar, Aetna Inc's (>> Aetna Inc.) acquisition of U.S. Healthcare and Roche Holding AG acquisition of Genentech.

"Gene has played a vital role in strengthening our investment banking franchise, particularly with respect to many of the most significant companies in technology and media," Blankfein and Cohn said in the memo, whose contents were confirmed by a spokesman.

(Reporting By Lauren Tara LaCapra in New York; editing by Andre Grenon)

By Lauren Tara LaCapra

Stocks mentioned in the article
ChangeLast1st jan.
AETNA 0.33% 175.63 Delayed Quote.-2.56%
GOLDMAN SACHS GROUP 1.79% 266.2715 Delayed Quote.3.39%
ROCHE HOLDING LTD. -0.56% 222.05 Delayed Quote.-9.41%
WALT DISNEY COMPANY (THE) 1.81% 107.22 Delayed Quote.-2.29%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AETNA
08:16pAETNA : Board of Directors Declares Quarterly Cash Dividend
BU
07:29aCVS HEALTH : Antitrust Subcommittee to Hold Hearing on CVS-Aetna Merger
AQ
02/22CVS HEALTH : House Judiciary Committee News Release
AQ
02/21AETNA : Announces New Accountable Care Agreement in Georgia with Sequent Health ..
PU
02/21Albertsons to buy Rite Aid as Amazon threat looms
RE
02/20AETNA INC /PA/ : Change in Directors or Principal Officers, Financial Statements..
AQ
02/19AETNA : Companies Pay Workers to Get Savvier With Money
DJ
02/19AETNA : Proton therapy for cancer has advanced, but not enough for insurance com..
AQ
02/15AETNA : Trademark Application for "INFORMED HEALTH" Filed by Aetna
AQ
02/15AETNA : Opens Support Lines to the Public Following Broward County School Shooti..
BU
More news
News from SeekingAlpha
03:18pFans Of CVS-Aetna Deal Should Enter Via Aetna Shares 
02:33pAetna declares $0.50 dividend 
02/22Tracking Dan Loeb's Third Point Portfolio - Q4 2017 Update 
02/20HHS debuts new rule allowing increased access to short-term insurance plans 
02/20Healthcare Innovation Or Exacerbating The Crisis? 
Financials ($)
Sales 2018 61 391 M
EBIT 2018 4 904 M
Net income 2018 3 382 M
Debt 2018 -
Yield 2018 1,06%
P/E ratio 2018 17,06
P/E ratio 2019 15,21
Capi. / Sales 2018 0,94x
Capi. / Sales 2019 0,89x
Capitalization 57 467 M
Chart AETNA
Duration : Period :
Aetna Technical Analysis Chart | AET | US00817Y1082 | 4-Traders
Technical analysis trends AETNA
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 206 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Mark T. Bertolini Chairman & Chief Executive Officer
Karen S. Lynch President
Margaret M. McCarthy Executive Vice President-Operations & Technology
Shawn M. Guertin CFO, Executive VP & Chief Enterprise Risk Officer
Harold L. Paz Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
AETNA-2.56%57 467
UNITEDHEALTH GROUP2.12%217 850
ANTHEM INC3.12%59 576
CIGNA-5.63%47 251
HUMANA7.38%38 055
CENTENE CORPORATION-0.67%17 291